Bumper Offer - Urjas oil Just @ Rs. 1
Gentamycin Eye Drop 5ml is a commercial drug that is prescribed in the form of Drops. It is primarily used for the treatment of Pneumonia. Secondary and off-label uses of Gentamycin Eye Drop 5ml have also been mentioned below.
The optimal dosage of Gentamycin Eye Drop 5ml is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Refer to the dosage section for a detailed discussion.
Some other side effects of Gentamycin Eye Drop 5ml have been listed ahead. Normally, these side effects of Gentamycin Eye Drop 5ml are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
Furthermore, you should know that effect of Gentamycin Eye Drop 5ml is Severe for pregnant women and Safe for women who are breastfeeding. Warnings related to Gentamycin Eye Drop 5ml's effects on the liver, heart and kidney, if any, have been listed below.
Gentamycin Eye Drop 5ml can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Gentamycin Eye Drop 5ml in conditions like Ulcerative Colitis, Gastritis, Parkinson's Disease.
Drug interactions for Gentamycin Eye Drop 5ml have been reported in the medical literature. Refer to the list below for further details.
In addition to these precautions, you may also note that Gentamycin Eye Drop 5ml is not safe while driving, and is is not addictive in nature.
Gentamycin Eye Drop 5ml is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Based on research, the following side effects have been observed when Gentamycin Eye Drop 5ml is used -
Is the use of Gentamycin Eye Drop 5ml safe for pregnant women?
Gentamycin (Cadila) can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Gentamycin Eye Drop 5ml safe during breastfeeding?
Gentamycin (Cadila) does not show any side effects in breastfeeding women.
What is the effect of Gentamycin Eye Drop 5ml on the Kidneys?
Gentamycin (Cadila) rarely affects the kidneys.
What is the effect of Gentamycin Eye Drop 5ml on the Liver?
Using Gentamycin (Cadila) does not have any harmful effects on the liver.
What is the effect of Gentamycin Eye Drop 5ml on the Heart?
You can take Gentamycin (Cadila) without any fear of damage to the heart.
Gentamycin Eye Drop 5ml should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Gentamycin Eye Drop 5ml unless your doctor advises you to do so -
Is this Gentamycin Eye Drop 5ml habit forming or addictive?
No, there is no any evidence that Gentamycin Eye Drop 5ml is addictive.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Gentamycin Eye Drop 5ml. So it is best to avoid driving.
Is it safe?
Yes, but take Gentamycin Eye Drop 5ml only as per medical advice.
Is it able to treat mental disorders?
No, Gentamycin Eye Drop 5ml cannot treat any kind of mental disorder.
Interaction between Food and Gentamycin Eye Drop 5ml
You can take Gentamycin Eye Drop 5ml with food.
Interaction between Alcohol and Gentamycin Eye Drop 5ml
Due to lack of research, there is no information about the side effects of taking Gentamycin Eye Drop 5ml with alcohol.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Gentamicin
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 747-748
